We are live on ! Find out more
SPRB

Spruce Biosciences

57 hedge funds and large institutions have $80.4M invested in Spruce Biosciences in 2026 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 14 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

967% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 3

367% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 3

78% more funds holding

Funds holding: 3257 (+25)

66% more capital invested

Capital invested by funds: $48.3M → $80.4M (+$32.1M)

0.19% more ownership

Funds ownership: 53.92%54.1% (+0.19%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
57
Holders Change
+25
Holders Change %
+78.13%
% of All Funds
0.7%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
32
Increased
14
Reduced
3
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Balyasny Asset Management
26
Balyasny Asset Management
Illinois
$655K -$1.56M -27,862 -70%
Dimensional Fund Advisors
27
Dimensional Fund Advisors
Texas
$477K +$493K +8,813 New
PAP
28
Persistent Asset Partners
Hong Kong
$415K +$288K +5,149 +204%
State Board of Administration of Florida Retirement System
29
State Board of Administration of Florida Retirement System
Florida
$388K +$402K +7,182 New
Bank of New York Mellon
30
Bank of New York Mellon
New York
$366K +$379K +6,779 New
Charles Schwab
31
Charles Schwab
California
$318K +$330K +5,896 New
Renaissance Technologies
32
Renaissance Technologies
New York
$254K +$263K +4,700 New
Morgan Stanley
33
Morgan Stanley
New York
$238K +$167K +2,996 +212%
PFCS
34
Pale Fire Capital SE
Czech Republic
$206K +$213K +3,818 New
RhumbLine Advisers
35
RhumbLine Advisers
Massachusetts
$190K +$197K +3,519 New
Deutsche Bank
36
Deutsche Bank
Germany
$143K +$148K +2,652 New
Wells Fargo
37
Wells Fargo
California
$126K +$130K +2,329 New
New York State Common Retirement Fund
38
New York State Common Retirement Fund
New York
$103K +$106K +1,900 New
Citigroup
39
Citigroup
New York
$68.3K +$18.2K +326 +35%
Mirae Asset Global ETFs Holdings
40
Mirae Asset Global ETFs Holdings
Hong Kong
$67.6K +$70K +1,252 New
JP Morgan Chase
41
JP Morgan Chase
New York
$63K +$63K +1,127 New
LPC
42
Lion Point Capital
New York
$54K
PFSRSONJ
43
Police & Firemen's Retirement System of New Jersey
New Jersey
$46.7K +$48.3K +864 New
Barclays
44
Barclays
United Kingdom
$36.4K +$37.7K +674 New
BNP Paribas Financial Markets
45
BNP Paribas Financial Markets
France
$24.5K +$25.3K +453 New
Vanguard Global Advisers
46
Vanguard Global Advisers
Pennsylvania
$24.4K
Legal & General Group
47
Legal & General Group
United Kingdom
$14.2K +$14.8K +264 New
AIP
48
Ameritas Investment Partners
Nebraska
$13.3K +$13.8K +247 New
TRCT
49
Tower Research Capital (TRC)
New York
$13.3K +$5.93K +106 +76%
Russell Investments Group
50
Russell Investments Group
United Kingdom
$11.7K +$12.1K +217 New

SPRB Hedge Fund Activity: Q2 2026 in Review

57 of the 8,153 institutional investors tracked by Wall St. Rank reported a position in Spruce Biosciences (SPRB) for Q2 2026, worth a combined $80.4M — up 66% from $48.3M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new SPRB positions and 3 closed out — a net gain of 29 holders — while 14 added to existing stakes and 3 trimmed.

The largest buyer was AIGH Capital Management, opening a new position worth an estimated $14M. The largest seller was Balyasny Asset Management, cutting an estimated $1.56M.

  • 57 institutional investors held Spruce Biosciences (SPRB) as of Q2 2026, up from 32 in Q1 2026.
  • Funds reported $80.4M of Spruce Biosciences stock for Q2 2026, up 66% quarter-over-quarter.
  • 32 funds opened new Spruce Biosciences positions in Q2 2026 and 3 closed out, a net change of +29 holders.
  • The largest Spruce Biosciences buyer in Q2 2026 was AIGH Capital Management, an estimated $14M added.
  • The largest Spruce Biosciences seller in Q2 2026 was Balyasny Asset Management, an estimated $1.56M sold.

Based on aggregated 13F filings for Q2 2026.